Targeting of RecQ Helicases as a Novel Therapeutic Strategy for Ovarian Cancer

被引:6
|
作者
Maity, Jyotirindra [1 ]
Horibata, Sachi [2 ,3 ,4 ]
Zurcher, Grant [1 ]
Lee, Jung-Min [1 ]
机构
[1] NCI, Womens Malignancies Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA
[2] NCI, Cell Biol Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA
[3] Michigan State Univ, Precis Hlth Program, E Lansing, MI 48824 USA
[4] Michigan State Univ, Coll Human Med, Dept Pharmacol & Toxicol, E Lansing, MI 48824 USA
基金
美国国家卫生研究院;
关键词
ovarian cancer; RecQ helicases; BLM; WRN; RECQL4; novel treatment; WERNER-SYNDROME PROTEIN; ROTHMUND-THOMSON-SYNDROME; SYNDROME GENE-PRODUCT; BLOOMS-SYNDROME; DNA-DAMAGE; FUNCTIONAL INTERACTION; ATM ACTIVATION; FANCONI-ANEMIA; BLM HELICASE; EXPRESSION;
D O I
10.3390/cancers14051219
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
RecQ helicases are essential for DNA replication, recombination, DNA damage repair, and other nucleic acid metabolic pathways required for normal cell growth, survival, and genome stability. More recently, RecQ helicases have been shown to be important for replication fork stabilization, one of the major mechanisms of PARP inhibitor resistance. Cancer cells often have upregulated helicases and depend on these enzymes to repair rapid growth-promoted DNA lesions. Several studies are now evaluating the use of RecQ helicases as potential biomarkers of breast and gynecologic cancers. Furthermore, RecQ helicases have attracted interest as possible targets for cancer treatment. In this review, we discuss the characteristics of RecQ helicases and their interacting partners that may be utilized for effective treatment strategies (as cancers depend on helicases for survival). We also discuss how targeting helicase in combination with DNA repair inhibitors (i.e., PARP and ATR inhibitors) can be used as novel approaches for cancer treatment to increase sensitivity to current treatment to prevent rise of treatment resistance.
引用
收藏
页数:14
相关论文
共 50 条
  • [31] The Therapeutic Potential of Targeting the HGF/cMET Axis in Ovarian Cancer
    Kim Moran-Jones
    Molecular Diagnosis & Therapy, 2016, 20 : 199 - 212
  • [32] Aberrant Cholesterol Metabolism in Ovarian Cancer: Identification of Novel Therapeutic Targets
    He, Jiangnan
    Siu, Michelle K. Y.
    Ngan, Hextan Y. S.
    Chan, Karen K. L.
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [33] Integrin-Linked Kinase Is a Novel Therapeutic Target in Ovarian Cancer
    Ulm, Michael A.
    Redfern, Tiffany M.
    Wilson, Ben R.
    Ponnusamy, Suriyan
    Asemota, Sarah
    Blackburn, Patrick W.
    Wang, Yinan
    ElNaggar, Adam C.
    Narayanan, Ramesh
    JOURNAL OF PERSONALIZED MEDICINE, 2020, 10 (04): : 1 - 15
  • [34] Folic acid tagged nanoceria as a novel therapeutic agent in ovarian cancer
    Hijaz, Miriana
    Das, Soumen
    Mert, Ismail
    Gupta, Ankur
    Al-Wahab, Zaid
    Tebbe, Calvin
    Dar, Sajad
    Chhina, Jasdeep
    Giri, Shailendra
    Munkarah, Adnan
    Seal, Sudipta
    Rattan, Ramandeep
    BMC CANCER, 2016, 16
  • [35] Targeting micro-RNAs by natural products: a novel future therapeutic strategy to combat cancer
    Alnuqaydan, Abdullah M.
    AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, 2020, 12 (07): : 3531 - 3556
  • [36] Monoclonal antibody targeting MUC1 and increasing sensitivity to docetaxel as a novel strategy in treating human epithelial ovarian cancer
    Wang, Li
    Chen, Hongmin
    Liu, FengHua
    Madigan, Michele C.
    Power, Carl A.
    Hao, Jingli
    Patterson, Kate I.
    Pourgholami, Mohammad H.
    O'Brien, Philippa M.
    Perkins, Alan C.
    Li, Yong
    CANCER LETTERS, 2011, 300 (02) : 122 - 133
  • [37] Targeting the Inhibitor of Apoptosis Proteins as a Novel Therapeutic Strategy in Medulloblastoma
    Keating, Joanna
    Tsoli, Maria
    Hallahan, Andrew R.
    Ingram, Wendy J.
    Haber, Michelle
    Ziegler, David S.
    MOLECULAR CANCER THERAPEUTICS, 2012, 11 (12) : 2654 - 2663
  • [38] Targeting Mismatch Repair defects: A novel strategy for personalized cancer treatment
    Begum, Rumena
    Martin, Sarah A.
    DNA REPAIR, 2016, 38 : 135 - 139
  • [39] Protein ubiquitination in ovarian cancer immunotherapy: The progress and therapeutic strategy
    Guo, Huiling
    Wei, Jianwei
    Zhang, Yuyan
    Wang, Li
    Wan, Junhu
    Wang, Weiwei
    Gao, Ling
    Li, Jiajing
    Sun, Ting
    Ma, Liwei
    GENES & DISEASES, 2024, 11 (06)
  • [40] Mitochondrial recoupling: a novel therapeutic strategy for cancer?
    Baffy, G.
    Derdak, Z.
    Robson, S. C.
    BRITISH JOURNAL OF CANCER, 2011, 105 (04) : 469 - 474